Excellent site... very informative...... Lots of up to date information about this company call fluidigum. Please keep posting...

Gajus Worthington

There are less expensive ways in developement to do digital pcr. Bye bye fluidigm.

Will they get bought? With 100+ instruments sold a company like Thermo might want them.

I don't know if it is a good place to work, but it does not have a future until the leadership changes. The company has been around for 10 years, but lives from funding to funding. You will see them constantly talking about revenues and machines. Do not assume this is a surrogate for profit. They never actually make money.

Is Fluidigm a good company to work for and have truly got a future. Any useful insights would be appreciated.

IPO pushed to the second half of 2010...or 2011...or...
revenues of 9M for the first half of 2009, anyone got numbers for the second half? previsions in 2010?

Fluidigm is now working with Pacific Biosciences, kind of a incestuous relation assuming the number of people who worked in both places.

More and more systems sold, Bayer is joining the list!

Until Livak and other former ABIers leave, there is no hope for this company. Too much baggage from the past.

Why wait until 2011? They can recycle the S-1 from 2008. If the Lithuanian can convince the BOD that he knows how to run a company, maybe he can convince Wall Street that Fluidigm will make a profit.

Yes 100 instruments out now!

Fluidigm is looking into expending its sales force, then what?

IPO in 2011?

"During the UBS Global Life Sciences Conference in September, Worthington noted that Fluidigm's revenues for the first six months of 2009 were $9.3 million, more than double its revenues of $4.4 million for the first half of 2008" It also seems that they now have more than a 100 instruments out now.

just raised huge money, will anyone really buy their product?

It does seem that any time and ABIers comes along companies start shooting in all directions. Fluidigm would have a fantastic in the field of molecular diagnostic but I haven't seen anything in that direction. Has anyone seen anything?
3M goes after H1N1, Fluidigm should do the same but multiplexing and also seeking multiple virus in on shot!

To the following comment:

"Management has a serious issue making decisions and focusing, the term paralysis of analysis would be appropriate in this case.

A shame really."

Insightful analysis. Indecision infects all sections of the company - R&D, manufacturing, sales, and marketing.

Where does the buck stop?

I want to say - thank you for this!,

The problem lies with Livak and other ABIers. They drown whatever hopes there were in the technology with lies and falsehoods within their past. Afraid they may be exposed, they just sit and wait until retirement from science.

This company has an interesting technology that they have no idea how to exploit. A unique capability is being limited by addressing niche markets with relatively small potential. Management has a serious issue making decisions and focusing, the term paralysis of analysis would be appropriate in this case.

A shame really.

But it is going in all directions, some is agricultural, Stem cells, Next generation sequencing... What market is being targeted? Can Fluidigm sustain the diversity without revenues?

I bookmarked this link. Thank you for good job!,

I bookmarked this link. Thank you for good job!,

Great. Now i can say thank you!,

Very cute :-)))),

Great. Now i can say thank you!,

ss.txt;0;0

ss.txt;0;0

Very interesting site. Hope it will always be alive!,

Very cute :-)))),

I want to say - thank you for this!,

dIg4LH I bookmarked this link. Thank you for good job!

Selling $11M more debt/equity and picking up an extra $750k in revenue from a state grant is an exciting way for Fluidigm to begin its second decade, which should end with GW raising round Q in 2019 and blaming the market crash of 2018 for the lack of an IPO.

Money keeps coming!

Fluidigm, maker of chips used in genetic analysis systems, has raised $10.7 million of a targeted $14 million round of debt, warrants, rights and securities, according to a regulatory filing with the Securities and Exchange Commission. The South San Francisco company recently announced that it will be launching a new chip to speed and enhance the study and genotyping of stem cells.
Significantly, Fluidigm’s co-founder is Stephen Quake, the Stanford professor of bioengineering who recently announced that he mapped his entire genome in one week for just $48,000 — a feat that rocked the genetic services market, including DNA-reading startups 23andMe and Navigenics. Fluidigm’s new product is based on a prototype developed by Quake.
Before now, Fluidigm brought in $750,000 in grant money from the California Institute for Regenerative Medicine.

Fluidigm has been "circling the bowl" for years now. Somewhere along the line someone had the "bright" idea of hiding in Singapore rather than staying put, close to the customer...or better yet close to a potential acquirer (Savior). The whole thing smells funny and it ain't durian I smell

So the exit strategy for investors would be a return of X 1/10? Hard to believe Fluidigm would get purchased for so little money!
After a dry round for IPO last year, is there another plan?

The biggest turd there has spoken! The company will smell better after a courtesy flush.

Piss poor business plan. He who owns the content owns the business.

Moral is low...fielding no content themselves, they are at the mercy of ABI/Invitrogen.

Great business model out the gate...poor to bankrupt model mid to end game. Figure this company gets bought out soon at 1.0x sales or stock swap --> ridding the former ABIers at Fluidigm another push out the door.

Makes sense!

Fluidigm is in the process of completing its planned consolidtaion of fab activities from South San Francisco to Singapore. Singapore previously housed all fab production and the current move is to consolidate the R&D fab into the operations in Singapore, resulting in an expansion of the R&D Laboratories in South San Francisco.

Fluidigm, a privately held biotech tools company, continues to grow despite the worldwide recession. It is on track to double its reveneue year-on-year. It is not yet profitable.

-- Howard High
Fluidigm

Is this information public?

Which one? the one in South San Francisco or the one in Singapore?